Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Anand A. Dalal
Patrick Gagnon-Sanschagrin
Rebecca Burne
Annie Guérin
Geneviève Gauthier
Tania Small
Polly Niravath
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Dose modification; Drug wastage; Economic burden; HR+/HER2− metastatic breast cancer; Oncology; Palbociclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：768 / 778
页数：10
相关论文
共 50 条
  • [41] Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer: a prospective, monocentric study
    Palumbo, Raffaella
    Quaquarini, Erica
    Saltalamacchia, Giuseppe
    Malovini, Alberto
    Lapidari, Pietro
    Tagliaferri, Barbara
    Mollica, Ludovica
    Teragni, Cristina Maria
    Barletta, Chiara
    Locati, Laura Deborah
    Sottotetti, Federico
    DRUGS IN CONTEXT, 2024, 13
  • [42] Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points
    Law, Ernest
    Gavanji, Roya
    Walsh, Sarah
    Haltner, Anja
    McTavish, Rebecca
    Cameron, Chris
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (02) : 109 - 120
  • [43] Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer From the US and Chinese Perspectives
    Zhang, Yingjie
    Zeng, Xiaohui
    Deng, Haijun
    Ma, Fang
    Peng, Ye
    Yi, Lidan
    Tan, Chongqing
    Peng, Liubao
    CLINICAL THERAPEUTICS, 2019, 41 (06) : 1175 - 1185
  • [44] Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2-Metastatic Breast Cancer Treated with Abemaciclib
    Smyth, Emily Nash
    Beyrer, Julie
    Saverno, Kimberly R.
    Hadden, Elizabeth
    Abedtash, Hamed
    DeLuca, Angelo
    Lawrence, Garreth W.
    Rybowski, Sarah
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (04) : 681 - 693
  • [45] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wang, Wei
    Lei, Wenqian
    Fang, Ziru
    Jiang, Ruiyuan
    Wang, Xiaojia
    BMC CANCER, 2024, 24 (01)
  • [46] First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN
    Martinez-Janez, N.
    Ezquerra, M. Bellet
    Sanchez, L. M. Manso
    Carrasco, F. Henao
    Torres, A. Anton
    Morales, S.
    Ortega, P. Tolosa
    Gil, V. L. Obadia
    Sampedro, T.
    Conejero, R. Andres
    Calvo-Martinez, L.
    Galve-Calvo, E.
    Lopez, R.
    de la Pena, F. Ayala
    Lopez-Tarruella, S.
    de Araguiz, B. A. Hernando Fernandez
    Ruiz, L. Boronat
    Cardenas, T. Martos
    Chacon, J. I.
    Anton, F. Moreno
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (01) : 57 - 65
  • [47] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wei Wang
    Wenqian Lei
    Ziru Fang
    Ruiyuan Jiang
    Xiaojia Wang
    BMC Cancer, 24
  • [48] Clinical efficacy of palbociclib-based therapy in women with HR+/HER2-metastatic breast cancer in the real- world setting for Chinese women: a comparison with the IRIS study
    Shangguan, C-F
    Jiang, M.
    Yang, C.
    Lou, G-Y
    Li, Y. T.
    Qu, Q.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (19) : 6138 - 6148
  • [49] Development of a Prognostic Factor Index Among Women With HR+/HER2- Metastatic Breast Cancer in a Community Oncology Setting
    Vidal, Gregory A.
    Carter, Gebra Cuyun
    Gilligan, Adrienne M.
    Saverno, Kim
    Zhu, Yajun Emily
    Price, Gregory L.
    DeLuca, Angelo
    Smyth, Emily Nash
    Rybowski, Sarah
    Huang, Yu-Jing
    Schwartzberg, Lee S.
    CLINICAL BREAST CANCER, 2021, 21 (04) : 317 - +
  • [50] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Piudo, Natalia Chavarria
    Blancas, Isabel
    Flores, Encarna Gonzalez
    Carrasco, Fernando Henao
    Alvarez, Pilar Lopez
    Pancorbo, David Morales
    Casado, Salvador Gamez
    Garrido, Maria de la Cabeza Lomas
    Garcia, Jose Manuel Rodriguez
    Guisado, Antonia Martinez
    Vega, Adrian Sanchez
    Borrego, Manuel Ruiz
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12) : 3131 - 3141
12345